Unfortunately, at least 50% of gliomas do not respond to TMZ, of which some patients are intrinsically positive for resistance-related genes, such as p53 mutation, homeostatic iron regulator (HFE) mutation, and O6-methylguanine-DNA alkyltransferase (MGMT) promoter unmethylation; the others acquire the resistance after TMZ administration (4). This evidence concerns the gene HFE and glioma.